Review highlights the growing evidence that aging is linked to reduced expression of long genes, offering insights into ...

Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory filing.

If anyone knows how to create a great anti-ageing skincare regime it's a beauty editor whose job it is is to look at products ...

Richmond, California-based BioAge Labs, Inc. was founded to develop a treatment for obesity and ... Medical Foundation / American Federation for Aging Research.

The term, considered by some to be ageist and offensive, is used to highlight both the economic opportunities created by an aging population and the challenges it may pose to society.

BioAge Labs filed confidentially on May 31, 2024. Goldman Sachs, Morgan Stanley, Jefferies, and Citi are the joint bookrunners on the deal. No pricing terms were disclosed.

Russian scientists are working on new anti-ageing treatments on the orders of a close aide of President Putin, who is reportedly consumed by the idea of eternal life. Research institutes have been ...

but anti-obesity drug developers have lured Wall Street and secured the backing of several venture capital heavyweights. BioAge will list its shares on the Nasdaq under the symbol "BIOA." ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

(Reuters) - BioAge Labs, a biotech startup collaborating with Eli Lilly for its obesity therapy, said on Tuesday it had filed for an initial public offering in the United States. The move comes months ...